Tuesday, November 22, 2011

More big pharma news, hope still for sale

As expected, heads turned after the FDA rejected Genentech's block-buster drug Avastin as a treatment for breast cancer. Avastin has many other uses, but even with the FDA sanction, the drug as breast cancer treatment will not be stopped completely.
no company wants to be cast as so heartless that it would deprive a seriously ill cancer patient of a drug that might offer hope, however slim.
Genentech hopes to continue to supply this vital service to its customers, extending hope to their patients, while they charge private insurance and the government as much as $90,000/yr. per patient. For the hope. You can still fill out a form to establish you're under a specific income level and qualify for a $30K reduction in the price. They're incredibly generous.

1 comment:

  1. This is not the first of your posts I've read, and you never cease to amaze me. Thank you, and I look forward to reading more.